Growing community of inventors

Aying, Germany

Rainer Boxhammer

Average Co-Inventor Count = 4.00

ph-index = 2

The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.

Forward Citations = 25

Rainer BoxhammerJan Endell (8 patents)Rainer BoxhammerMark Winderlich (7 patents)Rainer BoxhammerLisa Rojkjaer (4 patents)Rainer BoxhammerChristofer Samuelsson (4 patents)Rainer BoxhammerKonstantin Petropoulos (1 patent)Rainer BoxhammerMarkus Rückert (1 patent)Rainer BoxhammerPeter Kelemen (1 patent)Rainer BoxhammerLisa Rojkjaer (1 patent)Rainer BoxhammerDominik Pretscher (0 patent)Rainer BoxhammerRainer Boxhammer (8 patents)Jan EndellJan Endell (11 patents)Mark WinderlichMark Winderlich (7 patents)Lisa RojkjaerLisa Rojkjaer (5 patents)Christofer SamuelssonChristofer Samuelsson (4 patents)Konstantin PetropoulosKonstantin Petropoulos (4 patents)Markus RückertMarkus Rückert (1 patent)Peter KelemenPeter Kelemen (1 patent)Lisa RojkjaerLisa Rojkjaer (1 patent)Dominik PretscherDominik Pretscher (0 patent)
..
Inventor’s number of patents
..
Strength of working relationships

Company Filing History:

1. Morphosys Ag (6 from 88 patents)

2. Incyte Corporation (2 from 666 patents)


8 patents:

1. 12358983 - Combination of anti CD19 antibody with a BCL-2 inhibitor and uses thereof

2. 12194095 - Combinations and uses thereof

3. 11224654 - Combinations and uses thereof

4. 10617691 - Combination of an anti-CD19 antibody and a Bruton's tyrosine kinase inhibitor and uses thereof

5. 10308722 - Method for the treament of multiple myeloma or non-hodgkins lymphoma with anti-CD38 antibody in combination with thalidomine, lenalidomids, or pomalidomide

6. 9765152 - Method for the treatment of multiple myeloma or non-Hodgkins lymphoma with anti-CD38 antibody and bortezomib or carfilzomib

7. 9289490 - Combinations and uses thereof

8. 8877899 - Anti-CD38 antibody and lenalidomide or bortezomib for the treatment of multipe myeloma and NHL

Please report any incorrect information to support@idiyas.com
idiyas.com
as of
12/26/2025
Loading…